Brentuximab Vedotin
Showing 276 - 296 of 296
Hodgkin Lymphoma, Anaplastic Large-cell Lymphoma Trial in Belgium, Lithuania, Spain (brentuximab vedotin, Brentuximab vedotin
Completed
- Hodgkin Lymphoma
- Anaplastic Large-cell Lymphoma
- brentuximab vedotin
- Brentuximab vedotin and rifampicin
-
Brussels, Belgium
- +5 more
Mar 30, 2016
Anti-PD-1 and Chemotherapy for R/R Hodgkin Lymphoma
Completed
- Hodgkin Lymphoma
- Evaluate the improvement in response from the end of anti-PD-1 monotherapy
-
Pierre-BĂ©nite, FranceCentre Hospitalier Lyon Sud
Sep 7, 2018
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer Trial in Worldwide (CDX-011, Capecitabine)
Completed
- Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
-
Birmingham, Alabama
- +139 more
Mar 6, 2019
Anaplastic Large Cell Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma Trial in Philadelphia (biological, drug,
Terminated
- Anaplastic Large Cell Lymphoma
- Recurrent Childhood Anaplastic Large Cell Lymphoma
- monoclonal antibody SGN-30
- +8 more
-
Philadelphia, PennsylvaniaChildren's Oncology Group
Feb 14, 2018
Advanced Malignant Solid Tumor, Estrogen Receptor Negative, GPNMB Positive Trial (drug, biological, other)
Withdrawn
- Advanced Malignant Solid Neoplasm
- +17 more
- Glembatumumab Vedotin
- +4 more
- (no location specified)
Jul 17, 2018
Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Anemia, Refractory, With Excess of Blasts Trial in United States (brentuximab
Completed
- Acute Lymphoid Leukemia
- +3 more
- brentuximab vedotin
-
Birmingham, Alabama
- +28 more
Feb 5, 2016
Recurrent Adult Hodgkin Lymphoma Trial in New York (Brentuximab Vedotin, Laboratory Biomarker Analysis, Temsirolimus)
Completed
- Recurrent Adult Hodgkin Lymphoma
- Brentuximab Vedotin
- +2 more
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Nov 6, 2015
Metastatic gpNMB Expressing Triple Negative Breast Cancer Trial (glembatumumab vedotin)
No longer available
- Metastatic gpNMB Expressing Triple Negative Breast Cancer
- glembatumumab vedotin
- (no location specified)
May 17, 2018
Triple Negative Breast Cancer Trial (Glembatumumab Vedotin)
Withdrawn
- Triple Negative Breast Cancer
- Glembatumumab Vedotin
- (no location specified)
May 30, 2018
Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia Trial in Worldwide (Polatuzumab Vedotin, Rituximab)
Completed
- Non-Hodgkins Lymphoma
- Chronic Lymphocytic Leukemia
- Polatuzumab Vedotin
- Rituximab
-
Stanford, California
- +15 more
Jun 14, 2017
Disease, Hodgkin Trial in Canada, United States (brentuximab vedotin, doxorubicin, vinblastine)
Completed
- Disease, Hodgkin
- brentuximab vedotin
- +4 more
-
Rochester, Minnesota
- +3 more
Dec 17, 2014
Carcinomas, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic Trial in United States (brentuximab vedotin, rifampin, midazolam)
Completed
- Carcinomas
- +4 more
- brentuximab vedotin
- +3 more
-
Duarte, California
- +5 more
Dec 17, 2014
Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Non-Hodgkin Trial in Germany, United States (brentuximab vedotin)
Completed
- Disease, Hodgkin
- +2 more
- brentuximab vedotin
-
Birmingham, Alabama
- +8 more
Dec 11, 2014
Anaplastic Large-Cell Lymphoma Trial in United States (SGN-30 (anti-CD30 mAb))
Completed
- Anaplastic Large-Cell Lymphoma
- SGN-30 (anti-CD30 mAb)
-
Birmingham, Alabama
- +17 more
Dec 17, 2014
Lymphoma Trial (brentuximab vedotin)
Withdrawn
- Lymphoma
- brentuximab vedotin
- (no location specified)
Jul 24, 2013
GVHD Trial in Seattle (brentuximab vedotin, laboratory biomarker analysis, pharmacological study)
Withdrawn
- Graft Versus Host Disease
- brentuximab vedotin
- +2 more
-
Seattle, WashingtonFred Hutchinson Cancer Research Center/University of Washington
Jun 25, 2013
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin
Completed
- Adult Lymphocyte Depletion Hodgkin Lymphoma
- +4 more
- monoclonal antibody SGN-30
- +6 more
-
Chicago, IllinoisCancer and Leukemia Group B
Feb 10, 2015
Anaplastic Large Cell Lymphoma Trial in Houston (Cyclophosphamide, Doxorubicin HCl, vincristine sulfate)
Terminated
- Anaplastic Large Cell Lymphoma
- Cyclophosphamide
- +4 more
-
Houston, TexasM D Anderson Cancer Center
May 29, 2014